<DOC>
	<DOCNO>NCT01304589</DOCNO>
	<brief_summary>The primary aim study determine efficacy milnacipran reduce pain woman provoke vestibulodynia ( PVD ) , centrally mediate pain syndrome similar fibromyalgia , characterize severe pain vestibule ( out vagina ) . The investigator also determine whether associate symptom PVD , include psychological distress , impairment sexual function , physical function , quality life , correlate reduction vulvar pain .</brief_summary>
	<brief_title>Savella Treatment Provoked Vestibulodynia</brief_title>
	<detailed_description>This 18-week , open-label , flexible-dose `` proof concept '' trial woman diagnosis vestibulodynia evaluate baseline eligibility . Eligible patient openly treat 200 mg/d milnacipran ( maximum tolerate dose ) total 12 week . The study design involve 4 phase : screen washout , baseline assessment , dose escalation , stable-dose phase ( Figure 1 ) . After complete 2-week washout prohibit medication , patient enter 2-week baseline period , train use daily diary tampon test , baseline safety efficacy data record . Patients continue meet eligibility criterion end baseline period begin 6-week period dose escalation . All patient schedule receive total 12 week stable dose treatment 6-week dose-escalation period total 18 week drug exposure .</detailed_description>
	<mesh_term>Vulvodynia</mesh_term>
	<mesh_term>Vulvar Vestibulitis</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>1. woman 1854 year age , 2 . 'Friedrich 's Criteria ' must meet ( report great six continuous month vulvar symptom include insertional dyspareunia pain touch , demonstrate physical exam moderate severe tenderness light touch , localize vulvar vestibule [ positive Cotton Swab Test ] demonstration variable degree erythema vestibule ) , 3. average pain level `` 4 '' great 10point tampon test and/or average pain level `` 4 '' great sexual intercourse pain scale ( 0 = pain ; 10 = bad pain ever ) 2week screening period ( see Study Parameters Section ) , 4. willing use two form contraception study . 1. vulvar condition , include dermatosis , vulvitis , vulvar papillomatosis , atrophic vaginitis ( presence maturation index ) , 2. previous vestibulectomy , 3. active vaginal infection , 4. neuropathology , include seizure disorder syncopal episode , 5. pregnancy risk pregnancy use reliable birth control method least 3 month prior enter study , 6. breastfeeding , 7. major medical illness include chronic liver disease/hepatic impairment , renal impairment , narrowangle glaucoma , uncontrolled hypertension , 8. major psychiatric illness include substance abuse , 9. multiple allergy ( great three drug environmental agent ) , 10. use centrallyacting agent , include monoamine oxidase inhibitor , benzodiazepine , opiate , muscle relaxant , antidepressant within 2 week randomization study , 11. use topical lidocaine , within 2 week randomization study , show effective treatment woman , worsen symptom others . Subjects permit take acetaminophen , aspirin , nonsteroidal antiinflammatory drug rescue medication . They provide list allowable escape medication would constitute protocol deviation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>provoke vestibulodynia</keyword>
	<keyword>vulvodynia</keyword>
	<keyword>PVD</keyword>
</DOC>